carbamates has been researched along with Uveomeningoencephalitic Syndrome in 1 studies
Uveomeningoencephalitic Syndrome: A syndrome characterized by bilateral granulomatous UVEITIS with IRITIS and secondary GLAUCOMA, premature ALOPECIA, symmetrical VITILIGO, poliosis circumscripta (a strand of depigmented hair), HEARING DISORDERS, and meningeal signs (neck stiffness and headache). Examination of the cerebrospinal fluid reveals a pattern consistent with MENINGITIS, ASEPTIC. (Adams et al., Principles of Neurology, 6th ed, p748; Surv Ophthalmol 1995 Jan;39(4):265-292)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Encorafenib is a new BRAF inhibitor currently being tested in phase 3 clinical trials for advanced or metastatic melanoma as monotherapy or in combination with the MEK-inhibitor binimetinib." | 7.88 | Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma. ( Anastasopoulou, A; Diamantopoulos, PT; Gogas, H; Papaxoinis, G; Stoungioti, S, 2018) |
| " Encorafenib is a new BRAF inhibitor currently being tested in phase 3 clinical trials for advanced or metastatic melanoma as monotherapy or in combination with the MEK-inhibitor binimetinib." | 3.88 | Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma. ( Anastasopoulou, A; Diamantopoulos, PT; Gogas, H; Papaxoinis, G; Stoungioti, S, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diamantopoulos, PT | 1 |
| Stoungioti, S | 1 |
| Anastasopoulou, A | 1 |
| Papaxoinis, G | 1 |
| Gogas, H | 1 |
1 other study available for carbamates and Uveomeningoencephalitic Syndrome
| Article | Year |
|---|---|
Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma.
Topics: Aged, 80 and over; Benzimidazoles; Carbamates; Female; Humans; Melanoma; Protein Kinase Inhibitors; | 2018 |